Filtered By:
Condition: Peripheral Vascular Disease (PVD)
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 47 results found since Jan 2013.

Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
CONCLUSION: Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel. PMID: 26386102 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - September 21, 2015 Category: Drugs & Pharmacology Authors: Arif SA, D'Souza J, Gil M, Gim S Tags: Am J Health Syst Pharm Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial
Conclusion PAD patients have a high rate of ischaemic and bleeding events post ACS. The reduction of CV death, MI or stroke with ticagrelor compared with clopidogrel in PAD patients was consistent with the overall trial result although it did not reach statistical significance. Overall major bleeding was similar between the therapies.
Source: European Journal of Preventive Cardiology - May 6, 2015 Category: Cardiology Authors: Patel, M. R., Becker, R. C., Wojdyla, D. M., Emanuelsson, H., Hiatt, W. R., Horrow, J., Husted, S., Mahaffey, K. W., Steg, P. G., Storey, R. F., Wallentin, L., James, S. K. Tags: Original scientific papers Source Type: research

Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease
CONCLUSIONS: Compared to clopidogrel + low dose aspirin, the use of rivaroxaban 2.5 mg twice daily + low dose aspirin reduced the risk of MACE, CV death and stroke including ischemic stroke in patients with or at high risk for chronic CAD and/or PAD. These benefits of rivaroxaban 2.5 mg twice daily + low dose aspirin compared to clopidogrel + low-dose aspirin appear to be achieved without significantly increasing patients' risk of moderate-to-severe including ICH or fatal bleeding.PMID:34641745 | DOI:10.1080/03007995.2021.1991294
Source: Current Medical Research and Opinion - October 13, 2021 Category: Research Authors: Craig I Coleman Akshay A Kharat Brahim Bookhart William L Baker Source Type: research

Design and Rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) Trial
Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research

Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications
AbstractPurpose of ReviewPlatelets are activated upon interaction with injured vascular endothelium to form a primary hemostatic plug. Pathogenic thrombosis driven by platelet aggregation can occur in the setting of vascular disease leading to ischemic events. The use of antiplatelet agents has become a mainstay for prevention of the secondary complications of vascular disease. This review summarizes seminal and recent literature related to this area.Recent FindingsAspirin is a cornerstone of antiplatelet therapy for coronary artery disease and cerebrovascular disease for prevention of myocardial infarction, stroke, and va...
Source: Current Atherosclerosis Reports - November 4, 2017 Category: Cardiology Source Type: research

Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study
CONCLUSIONS: Patients suffering from cardiovascular events and mortality were characterized by prior cardiovascular events as compared to patients who did not experience any events. Antiplatelet therapy was not optimally protective despite high medication adherence, and HTPR was independently associated with the occurrence of events. More research is needed on alternative treatment strategies such as dual antiplatelet therapy or combinations with anticoagulant drugs.TRIAL REGISTRATION: The Medical Ethics Committee (METC) of the MUMC+ approved the study (NL63235.068.17) and the study was registered in the Netherlands Trial ...
Source: Atherosclerosis - January 10, 2023 Category: Cardiology Authors: B M M Kremers J H C Daemen H Ten Cate H M H Spronk B M E Mees A J Ten Cate-Hoek Source Type: research

Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy
ConclusionsGastroprotection with PPI therapy should be utilized in appropriately selected patients with coronary artery disease requiring DAPT, even if the patients are on low-dose aspirin. (Clopidogrel and the Optimization of Gastrointestinal Events Trial [COGENT]; NCT00557921)
Source: Journal of the American College of Cardiology - April 4, 2016 Category: Cardiology Source Type: research

The Development of Therapeutics for Peripheral Artery Disease A Unique Cardiovascular Risk Population ∗
Peripheral artery disease (PAD) primarily manifests as occlusive atherosclerosis in the peripheral circulation to the lower extremities (1). Symptomatic patients have either a profound exercise limitation or develop critical limb ischemia, and all of these patients are at heightened risk for major cardiovascular and ischemic limb events (2). Despite a severe morbidity and mortality risk, historically, little attention has been paid to developing targeted therapies to reduce this risk in patients with PAD (3). However, there were early signals that PAD may be responsive to potent antiplatelet therapy in the CAPRIE (Clopidog...
Source: Journal of the American College of Cardiology - June 7, 2016 Category: Cardiology Source Type: research

Antiplatelet agents in hemodialysis.
In conclusion, since CRF patients are one of the groups at highest risk for atherosclerotic events, it could be reasonable to use aspirin in HD patients. However, the bleeding risk in HD patients needs to be strongly evaluated, especially before starting dual AA treatment. PMID: 27928736 [PubMed - as supplied by publisher]
Source: Journal of Nephrology - December 7, 2016 Category: Urology & Nephrology Authors: Migliori M, Cantaluppi V, Scatena A, Panichi V Tags: J Nephrol Source Type: research

State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
CONCLUSION: This study contributes to the growing literature on secondary prevention add-on therapy, as results from these modeling analyses suggest adding vorapaxar to SC for patients at high atherothrombotic risk can provide long-term health benefits. PMID: 28277861 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - March 10, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease
After adjustment for baseline characteristics, patients with symptomatic peripheral artery disease (PAD) based on prior revascularization, rather than an abnormal ABI, had a higher rate of myocardial infarction (MI) and acute limb ischemia but with a similar composite rate of cardiovascular death, MI and stroke. No significant difference was found between ticagrelor and clopidogrel for reduction of cardiovascular or acute limb ischemic events.
Source: Journal of Vascular Surgery - March 23, 2017 Category: Surgery Authors: W.S. Jones, I. Baumgartner, W.R. Hiatt, G. Heizer, M.S. Conte, C.J. White Tags: Abstract Source Type: research